Safety of Ibogaine Administration in the Detoxification of Opioid-Dependent Individuals: A Descriptive Open-Label Observational Study

About this resource

This is a detailed introduction to the safety study by Knuijver and colleagues, not a full-text translation. It concerned 14 people who had not achieved abstinence with standard support and who sought withdrawal and abstinence while receiving opioid maintenance therapy. The primary purpose was not to establish treatment efficacy, but to systematically observe cardiac, cerebellar, and psychiatric or behavioral safety after a single ibogaine administration.

The paper notes that ibogaine has been associated with torsades de pointes, which can follow QTc prolongation, and with deaths, and that systematic observations of ataxia in humans have been scarce. It also discusses reports of possible improvements in withdrawal, craving, and abstinence, while characterizing the existing efficacy evidence as limited.

Study design

This descriptive, open-label observational study was conducted in the psychiatry department of a Dutch university medical center. It received ethics approval and written consent, was registered as EudraCT 2014-000354-11, and used a data safety monitoring board. Torsades de pointes, death, and unexpected serious adverse events were stopping criteria.

The 14 participants included 12 men and 2 women, with a median age of 48 years (interquartile range 44–51). Twelve were receiving methadone maintenance and two buprenorphine. The investigators selected a psychosocially stable group seeking abstinence and excluded known heart disease, QTc above specified thresholds, electrolyte abnormalities, severe hepatic or renal impairment, psychotic symptoms, severe depression, suicidality, and other conditions.

To reduce QT effects from maintenance medications and standardize conditions, participants were switched to oral morphine sulfate for eight days after admission. Ibogaine hydrochloride 10 mg/kg was administered orally four hours after the final morphine dose. Metoclopramide 20 mg was also given to prevent nausea. ECGs were obtained every 30 minutes for the first 12 hours and then for at least 24 hours according to QTc. Protocols were prepared for magnesium administration and cardiology monitoring if QTc exceeded 500 ms.

Assessments included Fridericia-corrected QTc, heart rate, blood pressure, the Scale for the Assessment and Rating of Ataxia (SARA), the Delirium Observation Screening Scale (DOS), and the Clinical Opiate Withdrawal Scale (COWS). SARA and COWS were assessed at 2, 6, 10, and 24 hours, and DOS hourly for the first 12 hours.

Content

Median baseline QTc was 411 ms, median heart rate 70 beats per minute, mean systolic blood pressure 129 mmHg, and mean diastolic blood pressure 78 mmHg. Every participant had a history of polysubstance use, but addiction-severity measures generally showed few problems outside the drug-use domain, indicating that the study involved a relatively stable, selected population.

The original article’s main observations concern QTc, bradycardia, reduced blood pressure, and ataxia after administration. Withdrawal and subjective experiences were also recorded, but observation lasted only 24 hours and this was not a comparative trial primarily designed to assess efficacy. The authors discussed how inhibition of the hERG potassium channel by ibogaine and noribogaine, individual variation in CYP2D6 metabolism, and noribogaine’s long half-life might contribute to individual differences in the magnitude and duration of QTc change. These are mechanistic interpretations connecting clinical observations with prior research; genotype and blood concentrations were not directly tested in this study.

Results

The PubMed abstract reports a mean maximum Fridericia-corrected QTc prolongation of 95 ms, with a range of 29–146 ms. Seven of 14 participants (50%) exceeded QTc 500 ms during observation, and six remained above 450 ms 24 hours after administration. No torsades de pointes was observed. Eight participants received magnesium according to protocol.

Every participant developed clinical cerebellar ataxia, generally peaking at 2–6 hours. It was most pronounced in gait and stance, and participants needed a nurse’s support to reach the bathroom. In the five who still had findings at 24 hours, the signs had resolved after another 24 hours. Seven of 14 developed bradycardia below 60 beats per minute; the median maximum heart-rate decrease was 9 beats per minute. No systolic hypotension below 90 mmHg occurred, and the median maximum blood-pressure decrease was 22 mmHg. Two participants vomited and none had a seizure.

DOS remained 0 throughout in 10 participants and only 1–2 in four, below the delirium threshold of 3. Participants reported waking dreams or relived memories for approximately 3–7 hours; observations included insufficient spatial orientation in some cases. Withdrawal measured by COWS was low at most time points, but three participants subjectively considered the intervention unsuccessful and resumed morphine within 24 hours. The finding that 11 had not resumed morphine within 24 hours does not show long-term abstinence or relapse prevention.

The original article contains a numerical discrepancy. The abstract gives mean maximum QTc prolongation as 95 ms (29–146 ms), while the main-text figure legend gives a mean of 102 ms, standard deviation 36 ms, and range 40–168 ms. This resource uses the abstract’s principal result and emphasizes the consistent categorical findings that 7/14 exceeded 500 ms and 6/14 remained above 450 ms after 24 hours.

Limitations

The study included only 14 participants who were psychosocially stable and excluded for heart disease, severe hepatic or renal impairment, and other conditions. They may have been selected toward lower risk than the broader population of chronic opioid users, and the findings cannot be generalized to a more diverse and medically complex population. The small sample had little ability to detect rare events such as torsades de pointes, seizures, or severe psychiatric symptoms. ECGs were not continuous recordings, so brief arrhythmias may have been missed.

Without a control group, confounding from metoclopramide, opioid withdrawal, and residual methadone cannot be completely excluded. The 10 mg/kg dose was toward the lower end of previously reported doses; safety at higher doses was not assessed. Observation focused on 24–48 hours and did not measure long-term neurologic outcomes, abstinence, renewed use, or daily functioning.

The study therefore did not establish an effective detoxification method, a long-term treatment, an optimal dose, risk prevention by magnesium, or safety in the general population. Zero cases of torsades de pointes does not mean there is no risk.

Safety

The finding the authors emphasized most was clinically meaningful, reversible QTc prolongation even at a relatively low single dose. QTc above 500 ms is a threshold associated with risk of adverse cardiovascular outcomes in drug overdose, and bradycardia may further increase the risk of torsades de pointes. The persistence of prolongation at 24 hours was discussed together with the possible contribution of noribogaine, which has a long half-life.

Ataxia occurred in every participant and, although transient, was severe enough to create a risk of falls and inability to move without assistance. No participant crossed the delirium threshold during the study, but waking dreams, vivid memories, visual experiences, and changes in orientation were observed. These findings came from a setting with screening, hospitalization, frequent ECGs, and emergency-response preparation; they do not support safety in nonmedical settings.

This detailed introduction is not an administration or withdrawal manual. In light of observed serious cardiac risks, it cannot be read as evidence that self-administration or unmonitored use is safe.

Source and rights

Original source: Knuijver T, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction. 2022;117(1):118–128. DOI: 10.1111/add.15448. PMID 33620733; PMCID PMC9292417.

The original article is published under Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0). This page is a detailed introduction rather than a full-text translation. It summarizes the research purpose, design, principal findings, safety, and limitations without exhaustively or verbatim reproducing the tables, full procedures, discussion, or references.